

This week in therapeutics

Indication	Target/marker/athway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Aromatase (CYP19A1; ARO)	<p>Gene expression profiles of breast cancer biopsies could help determine patient response to aromatase inhibitors. In patients with hormone-dependent breast cancer, 37 had a clinical response to neo-adjuvant treatment with the aromatase inhibitor Femara letrozole and 15 were resistant. Analysis of gene expression profiles identified 205 variables that differed between responders and nonresponders. The differential profiles were identified 10–14 days after letrozole treatment, which is before any other evidence of tumor response can be detected. Next steps include confirming the results in an additional neo-adjuvant study.</p> <p>Novartis AG markets Femara to treat breast cancer.</p> <p>SciBX 2(9); doi:10.1038/scibx.2009.348 Published online March 5, 2009</p>	Findings unpatented; available for licensing	<p>Miller, W. <i>et al.</i> <i>J. Clin. Oncol.</i>; published online Feb. 17, 2009; doi:10.1200/JCO.2008.16.8849</p> <p>Contact: William R. Miller, University of Edinburgh, Edinburgh, U.K. e-mail: w.r.miller@ed.ac.uk</p>